Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial, Novo Nordisk said in a release.The headline results ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

BioSpace remembers COVID-19 five years after the pandemic was declared, Novo Nordisk’s CagriSema again misses expectations as the company joins a lawsuit filed by drug compounders against the FDA, ...

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.